Skip to content
Screener

Disc Medicine IRON Total Liabilities

Total Liabilities at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$65.32B-15.4%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$7.12B+11.6%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$44M-12.0%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$82.4M-19.0%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$316.36M-8.0%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$3.72B+30.2%

Other financials

Income statement

See full
Operating income-$69.5M-74.0%
Net income-$63.5M-86.3%
EPS (diluted)-$1.65-61.8%

Balance sheet

See full
Cash & equivalents$88.9M-27.5%
Total debt$31.1M+1.4%
Total equity$688.4M+4.3%
Total assets$750.2M+5.8%

Cash flow

See full
Operating cash flow-$62.2M-50.4%
CapEx--100%
Free cash flow-$62.2M-47.4%

Valuation

See full
Market cap$2.97B+46.0%
Enterprise value$2.92B+50.2%

Returns & leverage

See full
Return on equity-35.8%+41.3pp
Debt / equity0.0×
Current ratio24×-13.6×

Where this comes from

Reported directly by Disc Medicine in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The source filing: Disc Medicine’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 8:33 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-205192
Line itemMarch 31,2026December 31,2025
Total current liabilities31,14236,641
Long-term debt, net29,36529,159
Operating lease liabilities, non-current1,2771,253
Total liabilities61,78467,053
Commitments and contingencies (Note 14)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized, no shares issued or outstanding as of March 31, 2026 and December 31, 2025
Common stock, $0.0001 par value; 100,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 38,190,464 and 37,890,616 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively44

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Disc Medicine's total liabilities?
Disc Medicine (IRON) reported total liabilities of $61.78M in Q1 2026.
How has Disc Medicine's total liabilities changed year-over-year?
Disc Medicine's total liabilities increased by 26.3% year-over-year, from $48.9M to $61.78M.
What is the long-term trend for Disc Medicine's total liabilities?
Over 5 years (2020 to 2025), Disc Medicine's total liabilities has grown at a 17.3% compound annual growth rate (CAGR), from $30.18M to $67.05M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.

Ask your AI about Disc Medicine's total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude